Movement Alert｜ZAI LAB Rises 5.03% in Regular Trading, RTW Fund Increases Stake by $247 Million as Post-Earnings Rally Extends

Market Focus08-13

On August 13, ZAI LAB rose 5.03% in regular trading, trading at HKD 20.6/share, with turnover of HKD 175 million.

On the news front, RTW Fund Group GP, LLC purchased 9.4745 million shares of ZAI LAB on August 11 at an average price of USD 26.05 per share, totaling approximately USD 247 million. Following the acquisition, RTW's stake increased from 5.97% to 6.75%, representing a significant vote of confidence from the institutional investor.

The move comes on the heels of ZAI LAB's Q2 earnings released on August 6, which showed product revenue of USD 105.8 million, up 11% quarter-over-quarter and exceeding market expectations by approximately USD 2.5 million, driven by stable performance of Zejula and continued sales growth of Efgartigimod. Citi expressed increased confidence that ZAI LAB's China business will stabilize in H2 and resume meaningful growth next year. The company's core pipeline asset Zoci received European Medicines Agency orphan drug designation, with upcoming ESMO clinical data expected to serve as a further catalyst. Post-earnings, the stock has cumulatively risen over 30%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111632601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111632601","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ZAI LAB Rises 5.03% in Regular Trading, RTW Fund Increases Stake by $247 Million as Post-Earnings Rally Extends","media":"Market Focus","content":"<p><p>On August 13, ZAI LAB rose 5.03% in regular trading, trading at HKD 20.6/share, with turnover of HKD 175 million.</p><p>On the news front, RTW Fund Group GP, LLC purchased 9.4745 million shares of ZAI LAB on August 11 at an average price of USD 26.05 per share, totaling approximately USD 247 million. Following the acquisition, RTW's stake increased from 5.97% to 6.75%, representing a significant vote of confidence from the institutional investor.</p><p>The move comes on the heels of ZAI LAB's Q2 earnings released on August 6, which showed product revenue of USD 105.8 million, up 11% quarter-over-quarter and exceeding market expectations by approximately USD 2.5 million, driven by stable performance of Zejula and continued sales growth of Efgartigimod. Citi expressed increased confidence that ZAI LAB's China business will stabilize in H2 and resume meaningful growth next year. The company's core pipeline asset Zoci received European Medicines Agency orphan drug designation, with upcoming ESMO clinical data expected to serve as a further catalyst. Post-earnings, the stock has cumulatively risen over 30%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ZAI LAB Rises 5.03% in Regular Trading, RTW Fund Increases Stake by $247 Million as Post-Earnings Rally Extends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ZAI LAB Rises 5.03% in Regular Trading, RTW Fund Increases Stake by $247 Million as Post-Earnings Rally Extends\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 10:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, ZAI LAB rose 5.03% in regular trading, trading at HKD 20.6/share, with turnover of HKD 175 million.</p><p>On the news front, RTW Fund Group GP, LLC purchased 9.4745 million shares of ZAI LAB on August 11 at an average price of USD 26.05 per share, totaling approximately USD 247 million. Following the acquisition, RTW's stake increased from 5.97% to 6.75%, representing a significant vote of confidence from the institutional investor.</p><p>The move comes on the heels of ZAI LAB's Q2 earnings released on August 6, which showed product revenue of USD 105.8 million, up 11% quarter-over-quarter and exceeding market expectations by approximately USD 2.5 million, driven by stable performance of Zejula and continued sales growth of Efgartigimod. Citi expressed increased confidence that ZAI LAB's China business will stabilize in H2 and resume meaningful growth next year. The company's core pipeline asset Zoci received European Medicines Agency orphan drug designation, with upcoming ESMO clinical data expected to serve as a further catalyst. Post-earnings, the stock has cumulatively risen over 30%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1111632601","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111632601","pubTimestamp":1786588676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, ZAI LAB rose 5.03% in regular trading, trading at HKD 20.6/share, with turnover of HKD 175 million.On the news front, RTW Fund Group GP, LLC purchased 9.4745 million shares of ZAI LAB...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"走势提醒|再鼎医药常规交易上涨5.03%，财报后涨势延续，RTW基金增持2.47亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On August 13, ZAI LAB rose 5.03% in regular trading, trading at HKD 20.6/share, with turnover of HKD 175 million.On the news front, RTW Fund Group GP, LLC purchased 9.4745 million shares of ZAI LAB on August 11 at an average price of USD 26.05 per share, totaling approximately USD 247 million. Following the acquisition, RTW's stake increased from 5.97% to 6.75%, representing a significant vote of confidence from the institutional investor.The move comes on the heels of ZAI LAB's Q2 earnings released on August 6, which showed product revenue of USD 105.8 million, up 11% quarter-over-quarter and exceeding market expectations by approximately USD 2.5 million, driven by stable performance of Zejula and continued sales growth of Efgartigimod. Citi expressed increased confidence that ZAI LAB's China business will stabilize in H2 and resume meaningful growth next year. The company's core pipeline asset Zoci received European Medicines Agency orphan drug designation, with upcoming ESMO clinical data expected to serve as a further catalyst. Post-earnings, the stock has cumulatively risen over 30%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111632601","isCrawlerRequest":true}